FDA places partial clinical hold on all selinexor trials

The US Food and Drug Administration (FDA) has placed a partial hold on all clinical trials involving selinexor according to Karyopharm Therapeutics, the company developing the drug. Selinexor is the first in a new class of drugs known as Selective Inhibitor of Nuclear Export (SINEā„¢) compounds which by inhibiting XPO-1 mediated nuclear-cytoplasmic protein transport, causes…

Details